<unk>  is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.
Tasosartan
Olmesartan
Losartan
Irbesartan
Candesartan
Cyclothiazide
Chlorothiazide 
Methyclothiazide